325 related articles for article (PubMed ID: 32828582)
1. Validation of the clinical utility of 4 guidelines in the initial triage of mucinous cystic lesions of the pancreas based on cross-sectional imaging: Experience with 188 surgically-treated patients.
Park RHS; Lim GRS; Wu JJY; Koh YX; Teo JY; Cheow PC; Chan CY; Ooi LLPJ; Chung AYF; Goh BKP
Eur J Surg Oncol; 2020 Nov; 46(11):2114-2121. PubMed ID: 32828582
[TBL] [Abstract][Full Text] [Related]
2. Are the Sendai and Fukuoka consensus guidelines for cystic mucinous neoplasms of the pancreas useful in the initial triage of all suspected pancreatic cystic neoplasms? A single-institution experience with 317 surgically-treated patients.
Goh BK; Tan DM; Thng CH; Lee SY; Low AS; Chan CY; Wong JS; Lee VT; Cheow PC; Chow PK; Chung AY; Wong WK; Ooi LL
Ann Surg Oncol; 2014 Jun; 21(6):1919-26. PubMed ID: 24504924
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the Sendai and 2012 International Consensus Guidelines based on cross-sectional imaging findings performed for the initial triage of mucinous cystic lesions of the pancreas: a single institution experience with 114 surgically treated patients.
Goh BK; Thng CH; Tan DM; Low AS; Wong JS; Cheow PC; Chow PK; Chung AY; Wong WK; Ooi LL
Am J Surg; 2014 Aug; 208(2):202-9. PubMed ID: 24530043
[TBL] [Abstract][Full Text] [Related]
4. Utility of the 2006 Sendai and 2012 Fukuoka guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas: A single-center experience with 138 surgically treated patients.
Hsiao CY; Yang CY; Wu JM; Kuo TC; Tien YW
Medicine (Baltimore); 2016 Sep; 95(38):e4922. PubMed ID: 27661043
[TBL] [Abstract][Full Text] [Related]
5. Cross Validation of the Monoclonal Antibody Das-1 in Identification of High-Risk Mucinous Pancreatic Cystic Lesions.
Das KK; Geng X; Brown JW; Morales-Oyarvide V; Huynh T; Pergolini I; Pitman MB; Ferrone C; Al Efishat M; Haviland D; Thompson E; Wolfgang C; Lennon AM; Allen P; Lillemoe KD; Fields RC; Hawkins WG; Liu J; Castillo CF; Das KM; Mino-Kenudson M
Gastroenterology; 2019 Sep; 157(3):720-730.e2. PubMed ID: 31175863
[TBL] [Abstract][Full Text] [Related]
6. Association of Preoperative Risk Factors With Malignancy in Pancreatic Mucinous Cystic Neoplasms: A Multicenter Study.
Postlewait LM; Ethun CG; McInnis MR; Merchant N; Parikh A; Idrees K; Isom CA; Hawkins W; Fields RC; Strand M; Weber SM; Cho CS; Salem A; Martin RC; Scoggins C; Bentrem D; Kim HJ; Carr J; Ahmad S; Abbott DE; Wilson GC; Kooby DA; Maithel SK
JAMA Surg; 2017 Jan; 152(1):19-25. PubMed ID: 27760255
[TBL] [Abstract][Full Text] [Related]
7. Can the location of the mural nodule indicate benign or malignant in branch duct-type intraductal papillary mucinous neoplasm of the pancreas?
Niiya F; Ohike N; Norose T; Takano Y; Azami T; Kobayashi T; Maruoka N; Wakabayashi T; Matsuo K; Tanaka K; Nagahama M
Pancreatology; 2020 Oct; 20(7):1379-1385. PubMed ID: 32873485
[TBL] [Abstract][Full Text] [Related]
8. Sendai and Fukuoka Consensus Guidelines Identify Advanced Neoplasia in Patients With Suspected Mucinous Cystic Neoplasms of the Pancreas.
Kaimakliotis P; Riff B; Pourmand K; Chandrasekhara V; Furth EE; Siegelman ES; Drebin J; Vollmer CM; Kochman ML; Ginsberg GG; Ahmad NA
Clin Gastroenterol Hepatol; 2015 Oct; 13(10):1808-15. PubMed ID: 25818077
[TBL] [Abstract][Full Text] [Related]
9. Fukuoka criteria accurately predict risk for adverse outcomes during follow-up of pancreatic cysts presumed to be intraductal papillary mucinous neoplasms.
Mukewar S; de Pretis N; Aryal-Khanal A; Ahmed N; Sah R; Enders F; Larson JJ; Levy MJ; Takahashi N; Topazian M; Pearson R; Vege SS; Chari ST
Gut; 2017 Oct; 66(10):1811-1817. PubMed ID: 27390303
[TBL] [Abstract][Full Text] [Related]
10. Factors Associated With Invasive Intraductal Papillary Mucinous Carcinoma of the Pancreas.
Hirono S; Kawai M; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Ueno M; Yanagisawa A; Yamaue H
JAMA Surg; 2017 Mar; 152(3):e165054. PubMed ID: 28122068
[TBL] [Abstract][Full Text] [Related]
11. [Diagnostic efficacy for predicting intraductal papillary mucinous neoplasms of the pancreas with high grade dysplasia or invasive carcinoma based on the surgery indications in different guidelines].
Li B; Guo SW; Shi XH; Shen S; Zhang GX; Gao SZ; Pan YQ; Xu XF; Jin G
Zhonghua Wai Ke Za Zhi; 2021 May; 59(5):359-365. PubMed ID: 33915626
[No Abstract] [Full Text] [Related]
12. Systematic review of the utility of 18-FDG PET in the preoperative evaluation of IPMNs and cystic lesions of the pancreas.
Srinivasan N; Koh YX; Goh BKP
Surgery; 2019 May; 165(5):929-937. PubMed ID: 30577952
[TBL] [Abstract][Full Text] [Related]
13. CT findings and clinical effects of high grade pancreatic intraepithelial neoplasia in patients with intraductal papillary mucinous neoplasms.
Kim MC; Kim JH; Jeon SK; Kang HJ
PLoS One; 2024; 19(4):e0298278. PubMed ID: 38683769
[TBL] [Abstract][Full Text] [Related]
14. Long-term Risk of Pancreatic Malignancy in Patients With Branch Duct Intraductal Papillary Mucinous Neoplasm in a Referral Center.
Pergolini I; Sahora K; Ferrone CR; Morales-Oyarvide V; Wolpin BM; Mucci LA; Brugge WR; Mino-Kenudson M; Patino M; Sahani DV; Warshaw AL; Lillemoe KD; Fernández-Del Castillo C
Gastroenterology; 2017 Nov; 153(5):1284-1294.e1. PubMed ID: 28739282
[TBL] [Abstract][Full Text] [Related]
15. The validity of the surgical indication for intraductal papillary mucinous neoplasm of the pancreas advocated by the 2017 revised International Association of Pancreatology consensus guidelines.
Watanabe Y; Endo S; Nishihara K; Ueda K; Mine M; Tamiya S; Nakano T; Tanaka M
Surg Today; 2018 Nov; 48(11):1011-1019. PubMed ID: 29961172
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic fat content may increase the risk of imaging progression in low-risk branch duct intraductal papillary mucinous neoplasm.
Kashiwagi K; Minami K; Seino T; Hirata K; Iwasaki E; Inoue N; Iwao Y; Kanai T
J Dig Dis; 2019 Oct; 20(10):557-562. PubMed ID: 31322828
[TBL] [Abstract][Full Text] [Related]
17. Branch-duct intraductal papillary mucinous neoplasm (IPMN): Are cyst volumetry and other novel imaging features able to improve malignancy prediction compared to well-established resection criteria?
Pozzi Mucelli RM; Moro CF; Del Chiaro M; Valente R; Blomqvist L; Papanikolaou N; Löhr JM; Kartalis N
Eur Radiol; 2022 Aug; 32(8):5144-5155. PubMed ID: 35275259
[TBL] [Abstract][Full Text] [Related]
18. Current recommendations for surveillance and surgery of intraductal papillary mucinous neoplasms may overlook some patients with cancer.
Nguyen AH; Toste PA; Farrell JJ; Clerkin BM; Williams J; Muthusamy VR; Watson RR; Tomlinson JS; Hines OJ; Reber HA; Donahue TR
J Gastrointest Surg; 2015 Feb; 19(2):258-65. PubMed ID: 25373706
[TBL] [Abstract][Full Text] [Related]
19. Surgical indication for intraductal papillary mucinous neoplasm without mural nodule ≥5 mm.
Tsumura A; Hirono S; Kawai M; Okada KI; Miyazawa M; Kitahata Y; Kobayashi R; Hayami S; Ueno M; Yanagisawa A; Yamaue H
Surgery; 2021 Feb; 169(2):388-395. PubMed ID: 32859391
[TBL] [Abstract][Full Text] [Related]
20. Predictors of Malignancy in "Pure" Branch-Duct Intraductal Papillary Mucinous Neoplasm of the Pancreas without Enhancing Mural Nodules on CT Imaging: A Nationwide Multicenter Study.
Kim TH; Woo YS; Chon HK; Hwang JH; Yoo KS; Lee WJ; Lee KH; Lee JK; Dong SH; Park CH; Park ET; Moon JH; Kim HG; Cho KB; Kim HJ; Lee SO; Cheon YK; Lee JM; Park JW; Kim MH
Gut Liver; 2018 Sep; 12(5):583-590. PubMed ID: 29730906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
